Skip to content
Axcess News – Lifestyle
Author:
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
June 23, 2026
MoonLake Immunotherapeutics Announces Proposed Public Offering
June 22, 2026
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
June 21, 2026
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
May 10, 2026
BioLab Holdings Earns Great Place to Work® Certification
March 31, 2026
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
March 28, 2026
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
March 5, 2026